Chronos Archive seal
The Human Record

John Henry Holliday

Case HR-NI007 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
August 14, 1851 – November 8, 1887
Synthetic DOB
2004-08-14
Index visit
2026-02-10 at age 21
Synthetic MRN
HR-NI007-SYN

Teaching objective: Diagnosis and six-month treatment of drug-susceptible cavitary pulmonary tuberculosis in a 21-year-old dentist under the ATS/CDC/IDSA guideline (three sputum smears, nucleic acid amplification, culture and susceptibility, HIV and hepatitis testing, baseline liver tests and vision checks, isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks then isoniazid and rifampin for eighteen weeks by video-observed therapy, stopping ethambutol on susceptibility results, monthly liver and symptom monitoring, release from isolation, two-month culture conversion, contact investigation, and public-health reporting), together with care for an alcohol use disorder that raises the risk of isoniazid liver injury (AUDIT, brief intervention, counseling, and a structured safety assessment with the 988 Suicide & Crisis Lifeline), and an honest account of a liver-monitoring gap.

Historical timeline

DateEventClaims
August 14, 1851Born in Griffin, Georgia.CLM-0001
1866His mother died of tuberculosis.CLM-0002
1872Graduated from the Pennsylvania College of Dental Surgery and began practicing dentistry in Atlanta.CLM-0003
1873Diagnosed with tuberculosis and advised to move to a drier climate.CLM-0004, CLM-0005
September 1873Arrived in Dallas, Texas.CLM-0005
November 8, 1887Died of tuberculosis in Glenwood Springs, Colorado.CLM-0007

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D John Henry Holliday was born on August 14, 1851, in Griffin, Georgia. confirmed John Henry "Doc" Holliday (1851-1887) supports
D In 1866 Holliday's mother died of tuberculosis.
Family history of pulmonary tuberculosis.
confirmed John Henry "Doc" Holliday (1851-1887) supports
D He enrolled at the Pennsylvania College of Dental Surgery in 1870 and graduated in 1872, then practiced dentistry in Atlanta before opening his own practice in Griffin.
Supports his occupation as a newly qualified dentist in the modern episode.
confirmed John Henry "Doc" Holliday (1851-1887) supports
Doc Holliday dies of tuberculosis supports
D Shortly after beginning his career as a dentist in Atlanta he developed a bad cough; doctors diagnosed tuberculosis and advised a move to a more arid climate. He developed chronic pulmonary tuberculosis.
Anchor for the modern pulmonary tuberculosis.
confirmed Doc Holliday dies of tuberculosis supports
John Henry "Doc" Holliday (1851-1887) supports
D He was diagnosed with tuberculosis in 1873 and moved west for a healthier, drier climate, arriving in Dallas, Texas, in September 1873.
Dates the diagnosis; the episode's true frame ends before the move.
confirmed Holliday, Doc (1852-1887) supports
John Henry "Doc" Holliday (1851-1887) supports
D He made his living at the card tables, aggravating his tuberculosis with heavy drinking and late nights.
Anchor for the modern alcohol use disorder; the source does not date the heavy drinking.
confirmed Doc Holliday dies of tuberculosis supports
D He died of tuberculosis in its final stages on November 8, 1887, in Glenwood Springs, Colorado, at the age of 36.
Recorded as a fact; the modern episode ends with cure.
confirmed John Henry "Doc" Holliday (1851-1887) supports
Holliday, Doc (1852-1887) supports
Doc Holliday dies of tuberculosis supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance active confirmed both_with_link CLM-0004, CLM-0005
S Alcohol use disorder, mild, with binge drinking active confirmed both_with_link CLM-0006
S Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-10 Hemoglobin [Mass/volume] in Blood 12.6 g/dL (low)
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-02-10 Leukocytes [#/volume] in Blood by Automated count 9.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-02-10 Platelets [#/volume] in Blood by Automated count 412 10*3/uL (high)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-02-10 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 34 U/L
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-02-10 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-02-10 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-02-10 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 92 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-02-10 Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 78 U/L (high)
Reference 8-61 U/L
http://loinc.org · 2324-2
S 2026-02-10 Albumin [Mass/volume] in Serum or Plasma 3.4 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-02-10 Creatinine [Mass/volume] in Serum or Plasma 0.86 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-02-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 124 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-10 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-10 Hemoglobin A1c/Hemoglobin.total in Blood 5.2%
Reference <=5.6%
http://loinc.org · 4548-4
S 2026-02-10 Visual acuity uncorrected Right eye by ETDRS eye chart 85
Reference >=80
http://loinc.org · 79878-5
S 2026-02-10 Visual acuity uncorrected Left eye by ETDRS eye chart 85
Reference >=80
http://loinc.org · 79879-3
S 2026-02-10 Total score [AUDIT] 15 http://loinc.org · 75624-7
S 2026-02-10 Total score [AUDIT-C] 9 http://loinc.org · 75626-2
S 2026-02-10 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-02-24 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 41 U/L
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-02-24 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 39 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-02-24 Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-02-24 Visual acuity uncorrected Right eye by ETDRS eye chart 85
Reference >=80
http://loinc.org · 79878-5
S 2026-02-24 Visual acuity uncorrected Left eye by ETDRS eye chart 84
Reference >=80
http://loinc.org · 79879-3
S 2026-02-24 Total score [AUDIT-C] 4 http://loinc.org · 75626-2
S 2026-03-17 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 52 U/L
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-03-17 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 47 U/L (high)
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-03-17 Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-03-17 Total score [AUDIT-C] 2 http://loinc.org · 75626-2
S 2026-04-14 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 U/L
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-04-14 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 35 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-04-14 Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-04-14 Total score [AUDIT-C] 1 http://loinc.org · 75626-2
S 2026-08-18 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 U/L
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-08-18 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-08-18 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-08-18 Hemoglobin [Mass/volume] in Blood 14.4 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-08-18 Total score [AUDIT-C] 3 http://loinc.org · 75626-2
S 2026-08-18 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-05-19 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 64 U/L (high)
Reference 7-56 U/L
http://loinc.org · 1742-6
S 2026-05-19 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 58 U/L (high)
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-05-19 Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-05-19 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 98 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-05-19 Total score [AUDIT-C] 4 http://loinc.org · 75626-2
S 2026-09-22 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-09-22 Total score [AUDIT-C] 3 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-10Body height178 cm8302-2S
2026-02-10Body weight58 kg29463-7S
2026-02-10Body mass index (BMI) [Ratio]18.3 kg/m239156-5S
2026-02-10Systolic blood pressure112 mm[Hg]8480-6S
2026-02-10Diastolic blood pressure70 mm[Hg]8462-4S
2026-02-10Heart rate104 /min8867-4S
2026-02-10Respiratory rate20 /min9279-1S
2026-02-10Body temperature37.8 Cel8310-5S
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry95 %59408-5S
2026-02-24Body height178 cm8302-2S
2026-02-24Body weight59 kg29463-7S
2026-02-24Body mass index (BMI) [Ratio]18.6 kg/m239156-5S
2026-02-24Systolic blood pressure114 mm[Hg]8480-6S
2026-02-24Diastolic blood pressure72 mm[Hg]8462-4S
2026-02-24Heart rate92 /min8867-4S
2026-02-24Respiratory rate18 /min9279-1S
2026-02-24Body temperature37.3 Cel8310-5S
2026-02-24Oxygen saturation in Arterial blood by Pulse oximetry96 %59408-5S
2026-03-17Body height178 cm8302-2S
2026-03-17Body weight61 kg29463-7S
2026-03-17Body mass index (BMI) [Ratio]19.3 kg/m239156-5S
2026-03-17Systolic blood pressure116 mm[Hg]8480-6S
2026-03-17Diastolic blood pressure72 mm[Hg]8462-4S
2026-03-17Heart rate84 /min8867-4S
2026-03-17Respiratory rate16 /min9279-1S
2026-03-17Body temperature36.8 Cel8310-5S
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-04-14Body height178 cm8302-2S
2026-04-14Body weight62.5 kg29463-7S
2026-04-14Body mass index (BMI) [Ratio]19.7 kg/m239156-5S
2026-04-14Systolic blood pressure116 mm[Hg]8480-6S
2026-04-14Diastolic blood pressure74 mm[Hg]8462-4S
2026-04-14Heart rate78 /min8867-4S
2026-04-14Respiratory rate16 /min9279-1S
2026-04-14Body temperature36.7 Cel8310-5S
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-18Body height178 cm8302-2S
2026-08-18Body weight65.5 kg29463-7S
2026-08-18Body mass index (BMI) [Ratio]20.7 kg/m239156-5S
2026-08-18Systolic blood pressure118 mm[Hg]8480-6S
2026-08-18Diastolic blood pressure74 mm[Hg]8462-4S
2026-08-18Heart rate72 /min8867-4S
2026-08-18Respiratory rate14 /min9279-1S
2026-08-18Body temperature36.6 Cel8310-5S
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-05-19Body height178 cm8302-2S
2026-05-19Body weight61.8 kg29463-7S
2026-05-19Body mass index (BMI) [Ratio]19.5 kg/m239156-5S
2026-05-19Systolic blood pressure108 mm[Hg]8480-6S
2026-05-19Diastolic blood pressure68 mm[Hg]8462-4S
2026-05-19Heart rate98 /min8867-4S
2026-05-19Respiratory rate16 /min9279-1S
2026-05-19Body temperature37.4 Cel8310-5S
2026-05-19Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-09-22Body height178 cm8302-2S
2026-09-22Body weight66 kg29463-7S
2026-09-22Body mass index (BMI) [Ratio]20.8 kg/m239156-5S
2026-09-22Systolic blood pressure118 mm[Hg]8480-6S
2026-09-22Diastolic blood pressure72 mm[Hg]8462-4S
2026-09-22Heart rate68 /min8867-4S
2026-09-22Respiratory rate14 /min9279-1S
2026-09-22Body temperature36.6 Cel8310-5S
2026-09-22Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Structured safety assessment

Current ideation
absent
Intent
absent
Plan
absent
Disposition
Routine outpatient care. A new serious diagnosis, isolation, and heavy drinking can raise suicide risk, so safety is reviewed at every visit. He saved the 988 Suicide & Crisis Lifeline in his phone. No firearm in the home

This assessment is synthetic and does not convert historical behavior into a present-day fact.

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Complete 182 doses of treatment under video-observed therapy within six months2026-08-18completedAll 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the end
Sputum culture negative at two months2026-08-18completedTwo-month culture showed no growth, so the continuation phase stayed at four months
No alcohol during treatment, to protect his liver2026-08-18activeNot fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the end
Return to work once he is no longer infectious2026-03-17completedReleased from home isolation after three negative sputum smears and back at work four weeks into treatment
Weight back to at least 64 kg by the end of treatment2026-08-18completed65.5 kg at the end of treatment, from 58.0 kg at diagnosis

Interventions

InterventionStatusGuideline
Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavilycompletedGL-ATS-TB-2016, GL-ATS-TB-2025
Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxinecompletedGL-ATS-TB-2016
Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutolcompletedGL-ATS-TB-2016, GL-ATS-HEPATOTOX-2006
Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health departmentcompletedGL-CDC-CONTACT-2005, GL-ATS-TB-2016
Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visitcompletedGL-USPSTF-ALC-2018, GL-SUD-2021, GL-SUICIDE-2024

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 John Henry "Doc" Holliday (1851-1887) New Georgia Encyclopedia (Georgia Humanities) scholarly
SRC-0002 Holliday, Doc (1852-1887) Encyclopedia of the Great Plains (University of Nebraska-Lincoln) scholarly
SRC-0003 Doc Holliday dies of tuberculosis HISTORY.com (A&E Television Networks) other
SRC-0004 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedBiographical facts from the New Georgia Encyclopedia, the Encyclopedia of the Great Plains, and HISTORY.com. The birth year conflict (1851 or 1852) is recorded. The heavy drinking is documented but undated; its placement at the time of diagnosis is synthetic.
safe messaging reviewnot_startedAlcohol claims are marked sensitive; the safety assessment records no current risk and gives the 988 Suicide & Crisis Lifeline; no contact is named; death recorded without detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.